-
Deep brain stimulation significantly increases "on" time, reduces dyskinesias, reduces "off" time, and improves various quality-of-life measures compared with best medical therapy in patients with moderate to advanced Parkinson's disease.
-
The spontaneous development of anti-amyloid antibodies may have an impact on the development of plaques and Alzheimer's disease.
-
Postanoxic status epilepticus does not necessarily imply irreversible and fatal brain injury.
-
Risk factors for spontaneous dissection of carotid and vertebral arteries include smoking, migraine, and a tall, thin body. Women are at increased risk of dissecting multiple arteries.
-
When compared with conventional disease-modifying anti-rheumatic drugs (DMARD), tumor necrosis factor (TNF)-Alpha antibody treatment for rheumatoid arthritis (RA) may increase the risk of herpes zoster.
-
-
The monoclonal antibody, rituximab, appears to benefit patients with myasthenia gravis that is refractory to other modalities.
-
-
Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Rate control vs rhythm control for atrial fibrillation continues to be debated with most of the evidence falling on the side of rate control in recent years, primarily because of adverse effects from anti-arrhythmics. A new drug may change that however.
